Pharmacokinetic and Pharmacodynamic Study of IDN-6556 in ACLF

Conatus Pharmaceuticals

Status and phase: Terminated; Phase 2

Conditions: Acute Alcoholic Hepatitis; Acute on Chronic Hepatic Failure; Acute Liver Failure; Liver Cirrhosis

Treatments: Drug: IDN-6556; Other: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT01937130

IDN-6556-02

Details and patient eligibility

About

The study will evaluate the pharmacokinetics, pharmacodynamics, safety and preliminary efficacy of IDN-6556 in subjects with cirrhosis of the liver who are hospitalized for more than 24 hours due to acute deterioration of liver function.

Enrollment: 23 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male or female subjects of minimum adult legal age (according to local laws for signing the informed consent document), able to provide written informed consent, and understand and comply with the requirements of the study

• Subjects with a clinical, radiological and/or histological diagnosis of cirrhosis

• Subjects having not required hospital admission within 4 weeks of screening for a complication of cirrhosis

• Subjects with an acute deterioration of liver function

• Subjects who meet one of the following criteria:

  1. Subjects with renal failure (defined as creatinine ≥ 2.0 to ≤ 3.4 mg/dL)
  2. Subjects with other single organ failure with i. Renal impairment (defined as an increase in creatinine of > 0.3 mg/dL from either an established prior Baseline level or if applicable, upon admission to hospital if prior level is unavailable; for inclusion, the creatinine level must be raised above normal levels), and/or ii. Hepatic encephalopathy grade I or II
  3. Subjects with two organ failures

• If a subject received steroids for alcohol-induced acute liver failure, he/she must be unresponsive to steroid therapy. Responsiveness is based on investigator discretion.

• Willingness to utilize two reliable forms of contraception (for both males and females of childbearing potential) from screening to one month after the last dose of study drug

Exclusion criteria

• Known infection with HIV
• Subjects with cirrhosis who develop decompensation at any time in the postoperative period following partial hepatectomy
• Subjects with evidence of uncontrolled infection defined as persistent bacterial culture positivity despite adequate antibiotic therapy
• Subjects with clinical evidence of disseminated intravascular coagulation
• Subjects with chronic and/or pre-existing kidney disease defined as eGFR (estimated glomerular filtration rate) of less than 30 mL/min for 3 months or longer
• Subjects who are hypotensive (defined as mean arterial pressure <70 mmHg) or require the use of inotropic support
• Subjects with evidence of significant and/or uncontrolled bleeding
• Subjects requiring mechanical ventilation
• Subjects with active or history of malignancies other than hepatocellular carcinoma (HCC) within Milan criteria or curatively treated skin cancer (basal cell or squamous cell carcinomas), unless adequately treated or in complete remission for five or more years
• Subjects previously exposed to IDN-6556
• History or presence of clinically concerning cardiac arrhythmias, or prolongation of Screening (pre-treatment) QT or QTc interval of > 480 milliseconds (msec)

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

23 participants in 4 patient groups, including a placebo group

IDN-6556 5 mg

Experimental group

Description:

Dosed twice daily

Treatment:

Drug: IDN-6556

IDN-6556 25 mg

Experimental group

Description:

Dosed twice daily

Treatment:

Drug: IDN-6556

IDN-6556 50 mg

Experimental group

Description:

Dosed twice daily

Treatment:

Drug: IDN-6556

Placebo

Placebo Comparator group

Description:

Dosed twice daily

Treatment:

Other: Placebo